Key Points
- Insider sale: Mark Sabag sold 144,180 shares at an average price of $34.99 on May 1 for $5,044,858.20, cutting his holding by 64.1% to 80,760 shares, according to the SEC filing.
- Analyst optimism: Multiple brokerages (Goldman Sachs, JPMorgan, Barclays, UBS, Scotiabank) have raised targets and issued buy/overweight ratings, leaving a consensus "Moderate Buy" with an average target of $41.56.
- Financials and ownership: Teva reported Q1 EPS of $0.53 on $3.98 billion revenue (ROE 43.53%, net margin 9.01%), and institutional investors hold 54.05% of the company with large positions added by firms like Norges Bank.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president directly owned 63,647 shares of the company's stock, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Christine Fox also recently made the following trade(s):
- On Thursday, March 5th, Christine Fox sold 7,924 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $31.67, for a total value of $250,953.08.
Teva Pharmaceutical Industries Stock Up 1.2%
TEVA stock opened at $35.36 on Tuesday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The stock has a market capitalization of $40.65 billion, a price-to-earnings ratio of 26.58, a PEG ratio of 3.23 and a beta of 0.86. The business's fifty day moving average price is $31.15 and its two-hundred day moving average price is $29.46.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.6 earnings per share for the current year.
Teva Pharmaceutical Industries News Roundup
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Analysts are repricing Teva’s upside — a recent writeup raised fair value to $40.09 (from $38.18), signaling a modest upgrade in how the Street frames Teva’s R&D execution, biosimilars ambitions and capital allocation prospects. How The Investment Story For Teva Pharmaceutical Industries (TEVA) Is Shifting With New Analyst Focus
- Positive Sentiment: Several brokerages have lifted TEVA price targets recently (reported raises to $40.00, $42.00 and $45.00), a direct catalyst for buy‑side interest and higher headline valuations. Price Target Raised to $45.00 Price Target Raised to $42.00 Price Target Raised to $40.00
- Positive Sentiment: Piper Sandler reiterated an “Overweight” rating, reinforcing institutional support and likely contributing to buying momentum. Piper Sandler Overweight Reiterated
- Positive Sentiment: Teva will present at the BofA Securities Health Care Conference (May 12). The company’s EVP of Global R&D & Chief Medical Officer will outline pipeline/R&D progress — a near‑term event that can move sentiment if management gives encouraging commercial or clinical updates. Teva to Present at the BofA Securities Health Care Conference
- Negative Sentiment: Recent insider selling: EVP Christine Fox sold 21,258 shares (~25% reduction in her position), which can be interpreted as a negative signal by some investors. SEC Filing — Christine Fox Sale
- Negative Sentiment: Another insider, Mark Sabag, sold 144,180 shares (a reported ~64% reduction), a larger disposition that may temper upside from analyst upgrades. SEC Filing — Mark Sabag Sale
Institutional Trading of Teva Pharmaceutical Industries
Several large investors have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. increased its stake in Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company's stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares during the last quarter. Phoenix Financial Ltd. lifted its stake in Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock worth $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock valued at $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company's stock valued at $1,167,323,000 after purchasing an additional 4,820,000 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently commented on TEVA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, April 30th. Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday, January 6th. Piper Sandler reaffirmed an "overweight" rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Finally, The Goldman Sachs Group increased their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $41.56.
Read Our Latest Report on TEVA
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
